A Phase 1/2 study of nivolumab and ruxolitinib in relapsed/refractory classical Hodgkin lymphoma

Recruiting Phase 1,Phase 2 NCT03681561

Study Description

A Study of the Combination of Two Drugs, Nivolumab and Ruxolitinib, in Patients with Classical Hodgkin Lymphoma that has Relapsed or Stopped Responding to Treatment

Study Details

Registry ID:: NCT03681561
Conditions:: Hodgkin Lymphoma
Phase:: Phase 1,Phase 2
Target Enrollment:: 54 participants
Start Date:: September 13, 2018
Age Range:: 18–999 years
Healthy Volunteers:: No

Study Locations (4 sites)

Ohio State University Comprehensive Cancer Center
Columbus, OhioUnited States, United States
University of Wisconsin
Madison, WisconsinUnited States, United States
University of Iowa Hospitals and Clinics
Iowa City, IowaUnited States, United States
University of Minnesota
Minneapolis, MinnesotaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →